Citizens Jmp Issues Positive Forecast for Lantheus (NASDAQ:LNTH) Stock Price

Lantheus (NASDAQ:LNTH) had its price target hoisted by equities research analysts at Citizens Jmp from $73.00 to $78.00 in a report released on Tuesday,Benzinga reports. The firm presently has a “market outperform” rating on the medical equipment provider’s stock. Citizens Jmp’s target price points to a potential upside of 6.30% from the company’s previous close.

Several other brokerages have also recently commented on LNTH. Weiss Ratings raised shares of Lantheus from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Tuesday, January 6th. Mizuho upped their price target on shares of Lantheus from $60.00 to $72.00 and gave the company an “outperform” rating in a research note on Wednesday, December 17th. Citigroup restated an “outperform” rating on shares of Lantheus in a research report on Tuesday. Finally, Truist Financial boosted their price objective on Lantheus from $80.00 to $82.00 and gave the stock a “buy” rating in a report on Thursday, December 18th. Six equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $78.83.

Lantheus Price Performance

NASDAQ LNTH opened at $73.38 on Tuesday. The firm’s 50 day moving average is $67.38 and its 200-day moving average is $59.68. The company has a quick ratio of 2.49, a current ratio of 2.67 and a debt-to-equity ratio of 0.51. The company has a market capitalization of $4.87 billion, a PE ratio of 30.66 and a beta of -0.08. Lantheus has a 12-month low of $47.25 and a 12-month high of $111.29.

Institutional Investors Weigh In On Lantheus

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Elevation Point Wealth Partners LLC bought a new stake in Lantheus in the second quarter worth approximately $26,000. Osterweis Capital Management Inc. purchased a new stake in Lantheus in the 2nd quarter valued at $36,000. Hantz Financial Services Inc. lifted its position in shares of Lantheus by 412.5% during the 3rd quarter. Hantz Financial Services Inc. now owns 492 shares of the medical equipment provider’s stock worth $25,000 after buying an additional 396 shares in the last quarter. First Horizon Corp bought a new stake in Lantheus during the third quarter worth $26,000. Finally, Smartleaf Asset Management LLC boosted its holdings in shares of Lantheus by 63.3% in the 4th quarter. Smartleaf Asset Management LLC now owns 508 shares of the medical equipment provider’s stock worth $34,000 after buying an additional 197 shares during the last quarter. 99.06% of the stock is currently owned by institutional investors.

About Lantheus

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.